SunBird Bio
CAMBRIDGE, MA · Biotechnology · 50 employees
Sunbird Bio is a leader in protein-based diagnostic tests, becoming the first company to overcome the challenge of accurately detecting and differentiating the specific proteins that aggregate, and therefore signal the presence of Alzheimer’s disease, with a simple blood draw. We are addressing the tremendous, growing need for more reliable and sensitive diagnostic tests to accelerate drug develop
Funding history
- Series series a — $14.0M — Oct 2024
- Funding Round — $23.2M — May 2023
- Funding Round — $18.0M — Dec 2021
- Funding Round — $46.7M — Jul 2021
- Funding Round — $26.1M — Jun 2020
Recent signals
- Oct 17, 2024: Sunbird Bio secures partnership funding for neurological diagnostic platform
- Oct 16, 2024: Raised $14.0M in Series series a
- May 12, 2023: Raised $23.2M
- Dec 17, 2021: Raised $18.0M
- Jul 01, 2021: Raised $46.7M
- Jun 12, 2020: Raised $26.1M
- Aug 06, 2018: Raised $26.1M
See plans & pricing → Track SunBird Bio’s funding, hiring, and signals — with verified contacts — on Fundz.